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The role of 18F-FDG PET-CT in the detection of unknown
primary malignancy: a retrospective study
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Background/aim: This study aimed to retrospectively evaluate the role of 18F-FDG PET/CT imaging in the detection of unknown
primary tumor sites in patients with a suspicious malignancy.
Materials and methods: We retrospectively examined the 18F-FDG PET/CT images of 50 unknown primary malignancy patients. The
malignancy of the lesions with increased 18F-FDG uptake on PET images was defined by interpreting the nondiagnostic CT images that
were obtained with the PET study. The primary tumor site was decided according to the combined PET/CT findings, and the results
were subsequently confirmed with a histopathological examination.
Results: Fifty patients (29 M; 21 F) aged 18–85 years were included in the study. The sample included 32 malignant and 18 benign lesions
according to the histopathological evaluation. 18F-FDG PET/CT study accurately identified malignant lesions in 28 (average SUVmax
± SD: 8.27 ± 7.22) and benign lesions in 12 (average SUVmax ± SD: 3.63 ± 3.07) patients; these findings were histopathologically
confirmed. PET/CT correctly detected the primary tumor site in 16 (50%) of 32 patients.
Conclusion: 18F-FDG-PET/CT identified the primary tumor site well in 50% of our cases. We propose that 18F-FDG PET/CT imaging
may help to accurately detect malignant lesions in patients with unknown primary tumors.
Key words: Fluor-18 fluorodeoxyglucose, positron emission tomography/computerized tomography, unknown primary tumor,
unknown malignancy, hypermetabolic lesions

1. Introduction
Unknown primary malignancies (UPMs) are histologically
proven tumor metastases that lack evidence of a primary
site. The early and rapid distribution of the disease, the
clinical failure of the primary tumor diagnosis, and
unexpected metastatic sites are the main features of UPM.
Between 5% and 10% of all cancer patients are diagnosed
with UPM; it is the tenth most frequent cancer and the
fourth most common cause of cancer-related death (1,2).
Despite the recent advances in diagnostic techniques, the
diagnosis and treatment of patients with carcinoma of
unknown primary origin remains a challenge in practice.
Conventional imaging modalities may detect the site
of the primary tumor in only 10%–35% of all cases. A
histopathological analysis or even an autopsy examination
may not identify a primary lesion (1–4). In this patient
population, the diagnosis of the primary tumor site is
often time consuming, costly, and complex. The low rate
of detection of the primary cancer is attributed to the size
of lesions, which are smaller than the spatial and contrast
* Correspondence: olgataskaya@yahoo.com
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resolution of the techniques used for diagnosis, or to the
involution of the primary mass due to limited angiogenic
competence (5,6). Early and accurate diagnosis of the
primary lesion dramatically changes survival of UPM
patients. The median survival time for patients with UPM
is short, almost 8 to 12 months; thus, the determination
of the exact location of the tumor and prompt initiation
of treatment can extend survival up to 23 months (3,7,8).
Recently, whole body 18F-FDG PET/ CT hybrid imaging
has gained wide application in the diagnosis and follow-up
of cancer patients. 18F-FDG PET can accurately detect the
primary lesion in 24%–53% of patients whose diagnoses
were negative based on conventional diagnostic procedures
(7,9–11). Initial studies of the diagnostic effect of 18F-FDG
PET/CT in UPM patients have revealed promising results.
The aim of this study was to evaluate the role of 18F-FDG
PET/CT imaging in the detection of unknown primary
tumor sites in patients with a suspicion of malignancy. We
also intend to supplement the literature with the results of
our experience.
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2. Materials and methods
We retrospectively examined 18F-FDG PET/CT images of
82 consecutive patients with UPM whose test results were
negative for conventional diagnostic procedures, including
CT, MRI, mammography, and endoscopy. Despite the
completion of comprehensive laboratory analyses for
all patients, the primary site of malignancy could not be
identified. A primary malignancy or at least one metastatic
site or pathological lesion was histologically proven in only
50 patients. We analyzed only these 50 patients because the
histopathological findings were used as the gold standard
to evaluate the PET/CT results. The institution’s Medical
Ethics Review Committee approved the study protocol,
and all patients provided written informed consent prior
to the PET/CT imaging. A complete medical history and
physical examination were performed for all patients.
None of the patients had a history of cancer or received
chemotherapy and/or radiation therapy prior to the
18
F-FDG PET/CT examination.
2.1. 18F-flurodeoxyglucose PET/CT
Dual-modality PET/CT was performed using a Gemini
TF TOF PET/CT scanner (Philips Medical Systems,
USA). All of the subjects fasted for at least 6 h prior to
imaging. The fasting blood glucose levels were measured
prior to the F-18 FDG injection, and patients with glucose
levels lower than 160 mg/dL received an intravenous
injection of 3.7 MBq/kg 18F-FDG. PET/CT scanning was
performed 60 min after the injection of 18F-FDG. Wholebody CT was performed using a 16-slice helical CT. The
CT scan data were collected at 50–120 mAs and 90–140
kV and were adjusted to the patient’s body weight. No
intravenous or oral contrast material was used. After the
CT scan, an emission scan was obtained from the head to
the feet at a rate of 20–60 s per frame. The attenuationcorrected PET images with CT data were reconstructed
using an ordered subset expected maximization (OSEM)
algorithm (33 subsets, 3 iterations). Commercial software
(Extended Brilliance Workspace, Philips Medical Systems)
was used to accurately coregister the CT and PET scan
data. The maximum standard uptake values (SUVmax)
were calculated using the attenuation-corrected images,
the amount of injected 18F-FDG, the body weight of each
patient, and the cross-calibration factors between the PET
and the dose calibrator. Two experienced nuclear medicine
physicians retrospectively visually and semiquantitatively
reviewed the PET, noncontrast CT, and fused PET/CT
images to locate the primary tumor. The nuclear medicine
physicians were informed about the clinical background
of patients, but were blinded to the results of the other
conventional imaging procedures. The two physicians
reached a consensus for all of the PET/CT results. On the
PET images, the primary tumor assessment was based
on the detection of focally increased glucose (18F-FDG)
metabolism with a SUVmax exceeding 2.5, whereas an

enhanced mass or lymph node was the criterion for
malignancy on nondiagnostic CT images. However,
malignancy was not solely based on hypermetabolic
18
F-FDG findings; these lesions were also classified as
malignant by evaluating the entire medical history,
conducting a physical examination, conducting laboratory
analysis of the patients, and correlating the nondiagnostic
CT images that were simultaneously obtained with a
PET study. The probable site of the primary tumor was
identified based on the combined findings of PET and CT.
All potential sites of the primary tumor described by PET/
CT were subsequently confirmed by histopathological
examinations. The rate of primary tumor detection
was determined based on comparing the PET/CT and
histopathological results. Ultimately, true and false positive
as well as true and false negative findings were defined
based on the histopathological results (Table 1). The
diagnosis of malignancy by 18F-FDG PET/CT, irrespective
of known or unknown primary focus, was classified as true
positive when it was proven to be a malignant lesion by
histopathological evaluation.
3. Results
The 50 patients were aged 18–85 years (average ± SD:
61.64 ± 16.26 years); 29 were male and 21 were female.
The clinical and histopathological data and the 18F-FDGPET/CT findings are reported in Table 1 according to the
site of the primary tumor. The lesion localizations of 50
patients on 18F-FDG PET/CT were evaluated (Table 2). The
histopathological evaluation of all 50 patients identified 32
malignant and 18 benign lesions. The 18F-FDG PET/CT
accurately depicted the lesions as malignant or metastatic
(Figure 1) in 28/32 (87%) patients (average SUVmax ± SD:
8.27 ± 7.22) compared with the histopathological findings.
The PET/CT correctly detected the primary tumor site in
16 (50%) of 32 patients: in the lungs in three cases (# 6,
14, and 23); the lymph nodes (lymphoma) (#15 and 31),
liver (# 12 and 22), stomach (# 5 and 20), and colon (#
4 and 21) in two cases; and the ovary (# 44), cerebrum
(# 19), soft tissue (ganglioneuroma) (# 42), kidney (#
3), and endometrium (#30) in one case. However, PET/
CT failed to identify the primary tumor site in 12 of the
32 patients (37.5%): the colon (Figure 2) in four cases
(# 17, 18, 39, and 49); the stomach (# 10 and 50), skin
malignancy (# 8 and 35), and malignant epithelial tumor
of unknown origin in two cases (# 36 and 37); and the soft
tissue malignancy (# 40) and a neuroendocrine tumor in
one case (# 38). In the remaining 4 of the 32 patients who
were histopathologically diagnosed as having a malignant
lesion, PET/CT could not identify the malignant lesion or
metastases (12.5%). Thus, our PET/CT results yielded a
false negative in 4 patients (average SUVmax ± SD: 0.95 ±
1.10) (liver, lung, colon, and soft tissue in patient # 24, 28,
29, and 41, respectively).

475

YAYLALI et al. / Turk J Med Sci
Table 1. Details of the FDG PET/CT findings in the search for a primary (n = 50 patients).
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Sex
M
M
F
M
M
M
M
F
M
F
F
F
M
M
F
M
M
F
M
F
M
M
M
M
F
F
F
F
M
F
M
M
F
M
M
M
F
M
M
F
M
M
F
F
F
M
F
F
M
F

Age
46
83
78
73
60
67
49
60
40
73
45
38
54
66
73
64
53
66
29
43
83
79
85
74
18
77
66
47
71
74
69
77
57
51
57
73
79
76
59
83
64
18
72
56
75
42
53
70
51
66

Histopathology
Inflammation
Infection
Renal cell cancer
Colon cancer (low differentiated)
Gastric ca. (Sarcoma met.)
Epithelial lung ca.
Benign lesion
Squamous cell ca. (skin)
Benign lesion
met lesion of gastric ca.
Inflammation
Hepatocellular ca.
benign
Malign epithelial lung tumor
Lymphoma (NHL)
inflammation
Colon adeno ca. met.
Met. lesion (low differentiated colon tumor)
Glioblastoma
Gastric adeno ca.
Met. of low differentiated colon tumor
Hepatocellular ca.
Lung adeno ca.
Met. of hepatocellular ca
Infection
Infection
Benign lesions
Adeno ca. met (colon or lung)
Colon adeno ca. met.
Endometrium adeno ca.
Hodgkin disease
inflammation
İnfectious disease
İnfectious disease
Met. lesion of squamous cell ca. (skin)
Malign epithelial tumor met.
Malign epithelial tumor met.
Neuroendocrine ca. met.
Colon adeno ca. met.
Soft tissue tumor met.
Liposarcoma
Ganglioneuroma
Benign lesion
Over ca.
İnfectious disease
Inflammation
Benign disease
Inflammation
met of colon adeno ca.
Gastric ca. met

PET/CT
Benign infectious nodule
Infection and inflammation
Primary renal tumor
Liver met lesions of colon cancer
Gastric tumor
Malign lung tumor
Benign lesion
Met. lesion of UPM
Benign
Met.lesion of UPM
Benign lesion
Primary liver tumor
Osteodegenerative findings
Primary lung tumor
Lymphoma
Met. LNs of UPM
Met. lesion of UPM
Met. lesion of UPM
Primary brain tumor
Primary gastric tumor
Rectal tumor
Liver tumor and met LNs
Primary lung tumor
Benign lesions
infection
Infection
Osteodegenerative findings
Infection
Infection
Endometrium tumor
Lymphoma
Met. of UPM
Malign disease
Malign disease
Met. lesion of UPM
Met. lesion of UPM
Met. lesion of UPM
Met. lesion of UPM
Met. lesion of UPM
Met. lesion of UPM
Benign infectious lesion
Ganglioneuroma
Osteodegenerative
Primary over ca. and met. lesions
Lung malignancy
Met. lesion
Benign disease
Malign disease
Met. lesion of UPM
Met. lesion of UPM

Results
TN
TN
TP
TP
TP
TP
TN
TP
TN
TP
TN
TP
TN
TP
TP
TN
TP
TP
TP
TP
TP
TP
TP
FN
TN
TN
TN
FN
FN
TP
TP
FP
FP
FP
TP
TP
TP
TP
TP
TP
FN
TP
TN
TP
FP
FP
TN
FP
TP
TP

F: female; M: male; TP: true positive; TN: true negative; FP: false positive; FN: false negative; met.: metastasis; LN: lymph node; UPM: unknown primary
tumor; ca.: cancer.
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Table 2. The patient numbers of malignant and benign results of the PET/CT and histopathological confirmation methods.
Histopathological evaluation
PET/CT evaluation
Total

Malignant

Benign

Total

Malignant

28

12

40

Benign

4

6

10

32

18

50

Figure 1. 18F-FDG PET/CT transverse images of a 43-year-old woman (Patient number 20) with an unknown primary tumor. PET (A),
CT (B), fusion (C), and MIP (D) images depict the primary tumor at the lesser curvature of the stomach with increased FDG uptake
(SUVmax= 4.51), which was later confirmed at histopathologic examination as gastric adenocarcinoma.

The 18F-FDG PET/CT accurately depicted lesions
as benign (Figure 3) in 12 (67%) of 18 patients, with
histopathological confirmation. In these 18 patients
diagnosed with a benign lesion and the 12 true negative
patients, the average SUVmax ± SD values were 3.95 ± 2.65
and 3.63 ± 3.07, respectively. In 6 of these 18 patients whose
average SUVmax ± SD value was 4.52 ± 1.38, the PET/CT
results yielded a false positive due to benign infectious and
inflammatory cytomorphology (patient numbers are 32,
33, 34, 45, 46, and 48) based on histopathology (33%).

4. Discussion
Unknown primary malignancies include a heterogeneous
group of malignant tumors that are generally accompanied
by metastases. The clinical features of patients may
widely vary and include enlarged lymph nodes anywhere
in the body, hepatosplenomegaly, bone pain, or fever
of unknown origin (1,2,12,13). Efforts to detect the
primary tumor with conventional imaging methods
in patients with UPM are often unsuccessful. This low
success of detection prevents the initiation of effective
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Figure 2. 18F-FDG PET/CT images of a 53-year-old man (Patient number 17) who presented with multiple liver lesions. Transaxial
PET (A), CT (B), fusion (C), and MIP (D) images demonstrate multiple hypodense lesions with pathologically increased FDG uptake
(SUVmax = 17.84) in the liver and pathologically enlarged, hypermetabolic portal–precaval lymph nodes (SUVmax = 14.70). An
excisional biopsy of the lesions and subsequent histopathological examination indicated metastatic colon adenocarcinoma.

treatment, which depends on tumor localization and
differentiation. Although unknown primary malignancies
are characterized by a poor prognosis, the identification of
the primary tumor permits the initiation of more specific
and effective treatments that improve survival. Therefore,
the detection of the primary lesion significantly changes
the prognosis and improves survival (10,14,15). In this
study, 18F-FDG PET/CT was able to conclusively identify
16 tumor sites among 32 primary malignant lesions,
and these findings were confirmed by histopathological
evaluation, which is accepted as the gold standard test.
However, the detection rates reported in the literature
significantly vary (24%–59%) (6–8,10,13,16–23).
We herein report a relatively higher rate of detection
(50%) of the primary tumor origin by 18F-FDG PET/
CT imaging as compared with many previous studies,
which reported detection rates ranging from 24% to
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45% (6,8,10,13,16,17,21–23). However, other previously
published studies reported a similar rate of detection of
the primary tumor origin (53%–59%) by 18F-FDG PET/
CT imaging (7,18–20). Another published article reported
a significantly higher detection rate (73%) of the primary
tumor origin by 18F-FDG PET/CT as compared with our
results and with those of other studies (24). This higher
rate may be due to insufficient diagnostic work-up (such
as medical history, physical examination, full blood count,
blood biochemistry analysis, and conventional imaging
methods). The results of another previously published
systematic review and metaanalysis indicate that FDGPET/CT study can detect 37% of primary tumors in
patients with unknown primary tumors, which constitutes
a rate lower than our detection rate (12). However, the
results from the subgroup analysis may not be precise
because of the small number of included studies.

YAYLALI et al. / Turk J Med Sci

Figure 3. 18F-FDG PET/CT transverse images of an 83-year-old man (Patient number 2) who presented with an unknown primary
tumor. PET (A), CT (B), fusion (C), and MIP (D) images show pulmonary nodules in the upper lobes of both the right and left lungs
with mild FDG uptake (SUVmax = 2.19), which was interpreted as a pulmonary infection. After PET/CT, a bronchoscopic biopsy was
performed and a subsequent histopathological examination confirmed the F-18 FDG PET/CT diagnosis by showing only infectious
findings in the specimens.

As a result of FDG being both captured and retained
within metabolically active cells, 18F-FDG can be used
to determine the high glycolytic activity of various
malignancies and imaging of these pathological lesions,
such as malignant melanoma, lung cancer, breast cancer,
gastrointestinal tract cancers, and genitourinary cancers,
can be provided by PET/CT. In our study, 18F-FDG PET/
CT correctly identified the primary tumor site in several
organs in 16 of 32 patients. In many other studies, the
most common site of the primary tumor was the lung
(4,8,12,18,21,22,25–27). However, we cannot directly
identify the most common localization site for the primary
tumor based on FDG PET/CT because the primary tumor
regions were heterogeneous in this study. However, the
most frequent primary tumor focus in our study was the
lung (three patients), followed by the liver, colon, and
lymph nodes (two patients each).

Despite the high detection rate of malignancies by
F-FDG PET/CT imaging, the 18F-FDG PET/CT may
not be able to detect final diagnosis of the primary site for
various types of neoplasms (6,16). In our study, 18F-FDG
PET/CT failed to identify the primary tumor site in 12
of 32 patients with histopathological findings; patients
had multiple organ metastases, and the malignancy
could not be identified in 4 patients with a malignant
histopathological diagnosis. The SUVmax values in the
lesions were low (<2.10) in these 4 patients. As known,
18
F-FDG uptake can be influenced by tumor grading. Highgrade tumors show elevated glucose consumption with
high FDG uptake, while uptake can be lower or absent in
low-grade tumors. In addition, some slow growing tumors
can metastasize, while some invasive tumors cannot grow
beyond 1–2 mm in size and thus remain subclinical (5,6).
Therefore, it is reported that the primary tumor remains
18

479

YAYLALI et al. / Turk J Med Sci
unidentified after autopsy in almost 70% of UPM cases
(1,2,4). Moreover, the primary lesion site is an important
factor for tumor identification with PET/CT. 18F-FDG is
not an optimal radiopharmaceutical for certain anatomical
locations that physiologically accumulate FDG. FDG
is well known to be physiologically accumulated in the
muscular, gastrointestinal, renal excretory systems, the
brain, and especially in inflammatory lesions. These
accumulation areas lead to uncertainty in the classification
of lesions (1,3,28). Hany et al. showed that 21% of all
lesions could not be specified with PET alone, and an
additional 7% of all lesions could be specifically classified
via the use of low-dose CT for image coregistration as a
result of a change in localization (29). Our 4 patients
with false negative results had a colon adenocarcinoma,
intraabdominal liposarcoma, lung adenocarcinoma, and
hepatocellular carcinoma, respectively. We think that our
false negative findings may be attributed to decreased
glucose consumption in the tumor tissues and/or their
inappropriate anatomical locations.
Some studies have revealed that 18F-FDG PET alone and
PET/CT imaging yielded similar results in the detection of
primary tumors of unknown origin (11,13). The efficiency
of FDG-PET for the detection of an UPM has been assessed
in a multicenter study of 208 patients, and 18F-FDG PET
detected a primary tumor in 24%–53% of the patients (11).
However, recent clinical studies that also aimed to identify
the primary lesion in UPM patients, similar to us, generally
relied on the use of hybrid PET/CT equipment instead of
PET alone. The hybrid system seems to be more accurate
than PET alone in assessing the presence and location
of tumoral lesions because it permits the simultaneous
acquisition of accurately aligned whole body anatomical
and functional images. Especially, PET/CT imaging is
significantly superior to PET alone in tumor staging. PET/
CT imaging can improve tumor staging by identifying
more lesions than conventional imaging methods
(6,29,30). Thus, FDG PET/CT is a very suitable technique
to identify a prognosis because the prognosis depends on
the accurate staging of the disease and the selection of the
most appropriate treatment approaches (22). PET/CT can
also direct a biopsy of the primary tumoral lesion and avoid
other unnecessary invasive investigations. In our study, the
detection of possible primary tumor locations guided the
biopsy, and the treatment was modified and adapted to
the location of the tumor in 16 patients based on 18F-FDG
PET/CT results alone.
Moreover, some situations may negatively affect the
identification of the primary tumor site with the FDG
PET/CT technique. 18F-FDG is not an optimal tracer for
inflammatory and infectious processes. False positive
results may be due to FDG uptake in benign conditions that
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feature increased glycolysis (e.g., pulmonary infarction)
or high physiological FDG uptake (e.g., muscle FDG
uptake) (10,12). These conditions may simulate cancer
and create false positive results. If the 18F-FDG PET/CT
findings indicate a malignancy, confirmatory invasive
diagnostic investigations, such as a biopsy, are necessary
because of the risk for false positivity (31). In our study, the
PET/CT results were false positive in 6 of 18 (33%) cases
with histopathologically proven benign disease (benign
infectious and inflammatory cytomorphology). These
infectious and inflammatory processes were mostly located
in the lung (in 4 of 6). The false positive rates in other similar
studies varied widely from 5.5% to 66.6% (8,10,13,16,22).
Similar to our findings, the lung has been reported as one
of two main locations in which false-positive FDG PET/
CT results are highest in patients with UPM. The second
main location is the oropharynx (12,25). The physiological
FDG uptake in this location may be misinterpreted as a
malignant lesion. False positive FDG-PET findings expose
the patient to advanced invasive diagnostic evaluations
(laryngoscopies and endoscopies), which incur associated
costs and morbidities. Therefore, talking, swallowing, and
chewing should be avoided in patients instantly before and
after FDG injection to decrease FDG levels in the muscles
of the larynx and pharynx (12,32). We strictly applied
these rules, and did not record false positive lesions in the
oropharyngeal or laryngeal region in any of the patients.
Previous studies indicated that both attenuation-corrected
and nonattenuation-corrected images need to be evaluated
to minimize the chance of misinterpreting artifacts as
malignant lesions (10,12,16,33).
Our study showed that 18F-FDG PET/CT accurately
depicted the malignant lesions in 28/32 patients whose
lesions were not identified by conventional tests, but were
histopathologically confirmed. Our results corroborate a
retrospective study that reported 26 true positive results for
33 patients (20). Our high sensitivity of 87% indicates that
18
F-FDG PET/CT can effectively identify malignancies.
18
F-FDG PET/CT is superior to conventional diagnostic
techniques, which could not identify the origin of the
primary malignancy in our patient group. The superior
performance of our PET/CT results as compared with
conventional imaging methods is attributed to the
whole-body PET/CT images that were analyzed by the
same experienced nuclear medicine physicians, while
conventional imaging methods were performed in
different and specific locations and the images were not
analyzed by the same radiologist. Our results support the
advantage of metabolic information over conventional
imaging methods in the search for a malignancy. We also
found that PET/CT can change the staging of the disease
by showing more lesions and more advanced disease than
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conventional imaging methods. It can also direct a biopsy
of the primary tumor (Figure 1) and avoid other invasive
procedures. Irrespective of its capability to detect an
unknown primary tumor, F-18 FDG PET/CT can detect or
rule out other possible metastatic sites, which is important
for patient therapeutic management and prognosis. We
think that 18F-FDG PET/CT is useful and highly sensitive
for the diagnostic work-up of patients with metastases of
unknown origin and can help explore the whole body in
a single and noninvasive examination. Furthermore, our
study is novel and more reliable and accurate than other
studies on the same topic that enrolled UPM patients
with different selection criteria, such as the exclusion of

cases with highly suspected clinical findings based on the
diagnostic work-up or the inclusion of cases with highly
suspected, but not histopathologically proven, malignant
or metastatic lesions.
18
F-FDG PET/CT identified the primary tumor site well
in 50% of our cases. Although validation is required with a
larger population, the present study indicates that 18F-FDG
PET/CT may help to accurately determine the lesion site
in patients with unknown primary tumors. However,
appropriate use and interpretation of 18F-FDG PET/CT
are necessary to maximize its diagnostic performance
for unknown primary malignancies and optimize the
management of these patients.
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